Bristol Myers Squibb is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, built on the new DGX Vera Rubin NVL72 systems. This advanced infrastructure will provide all scientists within the pharmaceutical giant access to powerful AI tools, including the NVIDIA BioNeMo Agent Toolkit, for accelerating drug discovery and development. The new system aims to eliminate compute limitations and waiting times, enabling faster research cycles, exploration of larger chemical spaces, and more efficient identification and optimization of potential drug candidates. AI
IMPACT Accelerates drug discovery timelines and expands research capabilities by providing unrestricted access to advanced AI compute.
RANK_REASON A major life sciences company is deploying a significant new AI infrastructure from a leading AI hardware provider.
Read on Mastodon — mastodon.social →
- Bristol-Myers Squibb
- Chelmodeyevskiy Maydan
- DGX SuperPOD
- DGX Vera Rubin NVL72
- Erin Davis
- NVIDIA
- NVIDIA BioNeMo Agent Toolkit
- Payal Sheth
- Vera Rubin
- CELMoD compounds
- Greg Meyers
- Robert M Plenge
AI-generated summary · Google Gemini · from 3 sources. How we write summaries →